Literature DB >> 22652101

Silver clear nylon dressing is effective in preventing radiation-induced dermatitis in patients with lower gastrointestinal cancer: results from a phase III study.

Tamim M Niazi1, Te Vuong, Laurant Azoulay, Corrie Marijnen, Kryzstof Bujko, Elie Nasr, Christine Lambert, Marie Duclos, Sergio Faria, Marc David, Bernard Cummings.   

Abstract

PURPOSE: For patients with anal canal and advanced rectal cancer, chemoradiation therapy is a curative modality or an important adjunct to surgery. Nearly all patients treated with chemoradiation experience some degree of radiation-induced dermatitis (RID). Prevention and effective treatment of RID, therefore, is of considerable clinical relevance. The present phase III randomized trial compared the efficacy of silver clear nylon dressing (SCND) with that of standard skin care for these patients. METHODS AND MATERIALS: A total of 42 rectal or anal canal cancer patients were randomized to either a SCND or standard skin care group. SCND was applied from Day 1 of radiation therapy (RT) until 2 weeks after treatment completion. In the control arm, sulfadiazine cream was applied at the time of skin dermatitis. Printed digital photographs taken 2 weeks prior to, on the last day, and two weeks after the treatment completion were scored by 10 blinded readers, who used the common toxicity scoring system for skin dermatitis.
RESULTS: The radiation dose ranged from 50.4 to 59.4 Gy, and there were no differences between the 2 groups. On the last day of RT, when the most severe RID occurs, the mean dermatitis score was 2.53 (standard deviation [SD], 1.17) for the standard and 1.67 (SD, 1.2; P=.01) for the SCND arm. At 2 weeks after RT, the difference was 0.39 points in favor of SCND (P=.39). There was considerable intraclass correlation among the 10 observers.
CONCLUSIONS: Silver clear nylon dressing is effective in reducing RID in patients with lower gastrointestinal cancer treated with combined chemotherapy and radiation treatment.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652101     DOI: 10.1016/j.ijrobp.2012.03.062

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Modern Dressings in Prevention and Therapy of Acute and Chronic Radiation Dermatitis-A Literature Review.

Authors:  Konrad Zasadziński; Mateusz Jacek Spałek; Piotr Rutkowski
Journal:  Pharmaceutics       Date:  2022-06-06       Impact factor: 6.525

2.  The effect and safety of dressing composed by nylon threads covered with metallic silver in wound treatment.

Authors:  Ariane R Brogliato; Paula A Borges; Janaina F Barros; Manuela Lanzetti; Samuel Valença; Nesser C Oliveira; Hélcio J Izário-Filho; Claudia F Benjamim
Journal:  Int Wound J       Date:  2012-08-21       Impact factor: 3.315

Review 3.  Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Raymond Javan Chan; Joan Webster; Bryan Chung; Louise Marquart; Muhtashimuddin Ahmed; Stuart Garantziotis
Journal:  BMC Cancer       Date:  2014-01-31       Impact factor: 4.430

4.  The safety and efficacy of EGF-based cream for the prevention of radiotherapy-induced skin injury: results from a multicenter observational study.

Authors:  Hyun-Cheol Kang; Seung-Do Ahn; Doo-Ho Choi; Min Kyu Kang; Woong-Ki Chung; Hong-Gyun Wu
Journal:  Radiat Oncol J       Date:  2014-09-30

5.  IGF-I and Hyaluronic Acid Mitigate the Negative Effect of Irradiation on Human Skin Keratinocytes.

Authors:  Celena A Sörgel; Rafael Schmid; Nina Stadelmann; Volker Weisbach; Luitpold Distel; Raymund E Horch; Annika Kengelbach-Weigand
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

Review 6.  Radiation-induced skin injury: pathogenesis, treatment, and management.

Authors:  Xiaojing Yang; Hanru Ren; Xiaomao Guo; Chaosu Hu; Jie Fu
Journal:  Aging (Albany NY)       Date:  2020-11-16       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.